Literature DB >> 15739617

Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.

Nigel Horscroft1, Vicky C H Lai, Wayne Cheney, Nanhua Yao, Jim Z Wu, Zhi Hong, Weidong Zhong.   

Abstract

Discovery of potential therapeutics against hepatitis C virus (HCV) infection has been hampered in the past decade by the inability to grow this virus in tissue culture and by the lack of robust small animal models. This situation has been improved by the recent development of a selectable HCV replicon cell culture system. For the first time, drug discovery scientists are able to screen large compound collections using the replicon cell culture system to identify small molecules with the potential to inhibit HCV RNA replication. The replicon system has also been used to elucidate inhibitors' antiviral mechanism of action and to optimize antiviral potency. In this review, we will summarize the recent development of HCV replicon cell culture system and its use in anti-HCV drug discovery. The antiviral activities of promising lead compounds are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15739617     DOI: 10.1177/095632020501600101

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  18 in total

1.  HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro.

Authors:  Mostafa K el-Awady; Ashraf A Tabll; Yasmine S el-Abd; Mahmoud M Bahgat; Hussein A Shoeb; Samar S Youssef; Noha G Bader el-Din; el-Rashdy M Redwan; Maha el-Demellawy; Moataza H Omran; Wael T el-Garf; Said A Goueli
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

2.  Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.

Authors:  Thierry Verbinnen; Herwig Van Marck; Ina Vandenbroucke; Leen Vijgen; Marijke Claes; Tse-I Lin; Kenneth Simmen; Johan Neyts; Gregory Fanning; Oliver Lenz
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

3.  Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment.

Authors:  David Paul; Simone Hoppe; Gesine Saher; Jacomine Krijnse-Locker; Ralf Bartenschlager
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

4.  Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.

Authors:  Il Hak Bae; Jin Kyu Choi; Chieyeon Chough; Sun Ju Keum; Heesun Kim; Sung Key Jang; B Moon Kim
Journal:  ACS Med Chem Lett       Date:  2013-12-04       Impact factor: 4.345

5.  Mutations conferring a noncytotoxic phenotype on chikungunya virus replicons compromise enzymatic properties of nonstructural protein 2.

Authors:  Age Utt; Pratyush Kumar Das; Margus Varjak; Valeria Lulla; Aleksei Lulla; Andres Merits
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

6.  Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon model.

Authors:  Qiu-Xia Fu; Li-Cui Wang; Shuai-Zheng Jia; Bo Gao; Yong Zhou; Juan Du; Ying-Li Wang; Xiao-Hui Wang; Jian-Chun Peng; Lin-Sheng Zhan
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

7.  SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.

Authors:  Meleri Jones; Morven E Cunningham; Peter Wing; Sampath DeSilva; Rupa Challa; Anjaneyulu Sheri; Seetharamaiyer Padmanabhan; Radhakrishnan P Iyer; Brent E Korba; Nezam Afdhal; Graham R Foster
Journal:  J Med Virol       Date:  2017-05-23       Impact factor: 2.327

8.  Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol.

Authors:  Eve-Isabelle Pécheur; Dimitri Lavillette; Fanny Alcaras; Jennifer Molle; Yury S Boriskin; Michael Roberts; François-Loïc Cosset; Stephen J Polyak
Journal:  Biochemistry       Date:  2007-04-25       Impact factor: 3.162

Review 9.  New hepatitis C virus drug discovery strategies and model systems.

Authors:  Snawar Hussain; Naina Barretto; Susan L Uprichard
Journal:  Expert Opin Drug Discov       Date:  2012-08-04       Impact factor: 6.098

10.  A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.

Authors:  Chi-Chen Yang; Han-Shu Hu; Ren-Huang Wu; Szu-Huei Wu; Shiow-Ju Lee; Weir-Torn Jiaang; Jyh-Haur Chern; Zhi-Shun Huang; Huey-Nan Wu; Chung-Ming Chang; Andrew Yueh
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.